General MedicationsBUCCALGeneric
NICOTINE POLACRILEX
NICOTINE POLACRILEX
Standard Dose
EQ 4MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview NICOTINE POLACRILEX is listed in Drugs@FDA under application 214354 (ANDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient NICOTINE POLACRILEX Form and strength GUM, CHEWING;BUCCAL - EQ 4MG BASE Sponsor FERTIN PHARMA Submission history Latest submission status date: 2022-12-21 00:00:00.
Structured Monograph
Clinical summary
Approval overview NICOTINE POLACRILEX is listed in Drugs@FDA under application 214354 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient NICOTINE POLACRILEX Form and strength GUM, CHEWING;BUCCAL - EQ 4MG BASE Sponsor FERTIN PHARMA Submission history Latest submission status date: 2022-12-21 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.